NeuroVax is an experimental vaccine that was studied as a possible treatment for relapsing remitting multiple sclerosis.
The development programme for NeuroVax was terminated when the company developing this treatment, Orchestra Therapeutics Inc, filed for bankruptcy in 2008. Immune Response BioPharma now owns the product and is planning phase II studies in secondary progressive MS.
These proposed studies have been delayed, and are now expected to complete in 2019.
How does it work?
NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin.
How is it given?
NeuroVax is injected into the muscle every four weeks.
What further studies are planned?
A study of NeuroVax, a novel therapeutic TCR peptide vaccine for SPMS of multiple sclerosis slowing disease progression via vaccination
This phase II study plans to recruit 150 participants with secondary progressive MS who will receive either Neurovax or placebo. Disability will be monitored (EDSS) over the 48 week study period.
Estimated start date March 2016
Estimated completion date March 2019
Further details of this study.
A study of NeuroVax, a novel therapeutic TCR peptide vaccine for SPMS of multiple sclerosis
This phase II study plans to recruit 200 participants with secondary progressive MS who will receive either Neurovax or placebo. The main measure of this study will be the number of active lesions seen on MRI scans.
Estimated start date February 2016. Estimated completion date February 2019. Further details of this study.
- Immunology 2008;123(1):66-78. Summary Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.